Nelson Vergel
Founder, ExcelMale.com
Scholar Rock, a small startup located in Cambridge, Massachusetts, revealed new data regarding lead drug candidate SRK-015 last week at the European Molecular Biology Organization’s annual meeting.
The compound is a “niche modulator inhibiting activation of the latent myostatin precursor,” explains the company’s announcement.
As NPR reports, myostatin is a type of protein that plays a role in suppressing muscle growth leading to diseases like muscular dystrophy or similar muscle-wasting conditions as a result of cancer, or even old age.
Preclinical data demonstrated SRK-015 was able to systematically block myostatin activation in vitro and was able to augment muscle strength in vitro while avoiding “undesirable” side effects, according to Scholar Rock’s statement.
http://www.dddmag.com/news/2015/09/...et_cid=4843618&et_rid=449166332&type=headline
The compound is a “niche modulator inhibiting activation of the latent myostatin precursor,” explains the company’s announcement.
As NPR reports, myostatin is a type of protein that plays a role in suppressing muscle growth leading to diseases like muscular dystrophy or similar muscle-wasting conditions as a result of cancer, or even old age.
Preclinical data demonstrated SRK-015 was able to systematically block myostatin activation in vitro and was able to augment muscle strength in vitro while avoiding “undesirable” side effects, according to Scholar Rock’s statement.
http://www.dddmag.com/news/2015/09/...et_cid=4843618&et_rid=449166332&type=headline
